Navigation Links
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
Date:6/13/2008

Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current

CML and ALL Therapies

COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. XL228 is a small molecule inhibitor of BCR-ABL, SRC, and insulin-like growth factor type 1 receptor (IGF1R), which are associated with cancer cell proliferation, survival, and metastasis. The compound also potently inhibits the T315I mutant form of BCR-ABL, which is resistant to all currently approved inhibitors. Dr. Jorge Cortes, Professor of Medicine, Deputy Chair, Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, and an investigator on the phase 1 trial, presented the data in a poster session (Abstract #1260) at the 13th Congress of the European Hematology Association.

Seventeen subjects have received at least one dose of XL228, of whom 16 had completed Cycle 1 as of May 15, 2008. The trial is evaluating a treatment cycle consisting of 4 weekly 1-hour IV infusions of XL228 at doses ranging from 0.45 mg/kg to 7.2 mg/kg. Thirteen of the 17 subjects (76.5%) have BCR-ABL mutations, including seven (41.2%) with the T315I mutation. At the 3.6 and 7.2 mg/kg doses (either as part of Cohorts 4 and 5 or through dose escalation from a previous cohort), all subjects have demonstrated stable or decreasing white blood cell counts. A CML patient with an F317L BCR-ABL mutation in lymphoid blast crisis experienced
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
2. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
3. Exelixis Announces First Quarter 2008 Financial Results
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
6. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
7. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
8. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
9. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 Sangamo BioSciences, Inc. (NASDAQ: ... release its second quarter 2015 financial results after the ... release will be followed by a conference call at ... public via telephone and webcast. During the conference call, ... discuss other business matters. The conference call ...
(Date:7/29/2015)... July 29, 2015  Depomed, Inc. (Nasdaq: DEPO ... for the quarter ended June 30, 2015. ... pain and neurology marketplace, with significant net product revenue ... value to our shareholders in both the immediate and ... Depomed. "Growth in the second quarter was led by ...
(Date:7/29/2015)... Fla. , July 29, 2015 The ... new balloon device called the ReShape Integrated Dual Balloon ... medications and surgery for people with obesity and one ... for Metabolic and Bariatric Surgery (ASMBS), the nation,s largest ... and gratified that after careful review the FDA has ...
Breaking Medicine Technology:Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 3Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 4Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 5Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 6Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 7Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 8Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 9Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 10Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 11Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 12Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 13Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 14Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 15American Society for Metabolic and Bariatric Surgery Views New Balloon Device For Obesity As Bridge Between Medications And Bariatric Surgery 2American Society for Metabolic and Bariatric Surgery Views New Balloon Device For Obesity As Bridge Between Medications And Bariatric Surgery 3
... 15, 2011 Fuisz ( www.fuisz.com ) today announced ... for Permitting Stage Door Access to On-Line Vendor Information"). ... stated, "This patent covers a system that allows a ... access a product supplier database through the on-line vendor,s ...
... Perrigo Company (Nasdaq: PRGO ; TASE) today ... TEVA ) (previously Barr Laboratories Inc.) has begun shipping ... applicant to file a complete ANDA with a Paragraph IV ... with 180 days of generic exclusivity. The Hatch Waxman litigation ...
Cached Medicine Technology:Perrigo Announces Launch of the Generic Version of Nasacort® AQ 2Perrigo Announces Launch of the Generic Version of Nasacort® AQ 3
(Date:7/29/2015)... ... July 29, 2015 , ... Potomac Pilates, an elite Washington, D.C. ... to Rock the Reformer ® by Potomac Pilates. On Thursday, July 30, Potomac ... the Reformer ® by Potomac Pilates will continue to offer the same classes and ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start ... to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... component, delivery model, application, end user and region. Factors such as the rising ... about benefits of analytics, and increase in venture capital investments are driving market ...
(Date:7/29/2015)... Miami, FL (PRWEB) , ... July 29, 2015 , ... ... on fruit flies revealed a gene which is directly responsible for stimulating and perpetuating ... was published in the journal entitled Proceedings of the National academy of Sciences, and ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the ... drug or alcohol addiction and mental health disorders. Acu-detox may begin taking off in ... recovering from drug and alcohol addiction. Although acupuncture is not a new practice, it ...
Breaking Medicine News(10 mins):Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3
... in a number of issues which is corrupting the system, ... dwindling// numbers of health workers, has left very little to ... Medical Association president Dr Mukesh aikerwal said "There is a ... and save in order to fund a $200,000-plus medical degree. ...
... lugworm has aroused scientists' curiosity, as a potential provider of ... The red liquid that courses through our veins, very much ... is a huge scamper for blood during complex surgeries to ... seems to have many secrets in store, and a little ...
... Federal Government's practice nurse subsidy should be offered to all ... today.// ,"Family doctors want to look after ... ways to provide the best possible health care at a ... ,"Integrating nurses into general practice makes sense to them ...
... hour per day of exercise at least to help stave ... study has suggested that even more activity may be needed. ... School of Sports Science, Oslo said, ‘Current guidelines for physical ... good health. We would suggest 90 minutes per day to ...
... Delhi High Court today upheld the decision of the BSF ... found suffering from 50 percent disability on account of contracting ... clarified that the termination was being upheld on the ground ... not because of his contracting HIV., ,A Division Bench ...
... of North Bengal claiming 88 lives and afflicting more than ... an RSP legislator in West Bengal said today.// ... that 48 deaths had been reported from Alipurduar sub-division alone., ... into the matter which, he alleged, "tends to go out ...
Cached Medicine News:Health News:A Worm Turns: Banking on Blood From a Little Lugworm 2Health News:Call For Better Funding Of Doctor-Nurse Teams 2Health News:Children Need to Exercise More to Prevent Heart Trouble 2Health News:Children Need to Exercise More to Prevent Heart Trouble 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
Medicine Products: